MitraClip EXPAND G4 Study
- Conditions
- Mitral Valve RegurgitationMitral Regurgitation
- Registration Number
- NCT04177394
- Lead Sponsor
- Abbott Medical Devices
- Brief Summary
This primary objective of the EXPAND G4 study is to confirm the safety and performance of the MitraClip G4 System in a post-market setting.
- Detailed Description
This is a post-market, multi-center, single-arm, prospective study to assess the safety and performance of the next generation MitraClip G4 System. The current protocol describes the design of this post-market study.
Up to 1,100 post-market, consented patients will be treated with a MitraClip G4 device according to local guidelines and IFU from the Europe and Middle East, the United States, Canada and Japan, and will be included in the analysis for the MitraClip EXPAND G4 Study. Follow-up echocardiograms will be collected at Discharge, 30 days and 1 year and 5 year at post-procedure visits. Additional clinical follow-up visits will be at 6 months (phone call), 2, 3, 4 year (office visits). Cardiovascular adverse events will be reported through 5 years to confirm safety of the MitraClip G4 System.
During the Phase 1 of the study 100 subjects were enrolled at 15 sites in the United States with the goal of evaluating the early safety and procedural outcomes associated with the MitraClip G4. The follow up duration was 30 days. Phase I was completed August 2020.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1164
- Subjects scheduled to receive the MitraClip per the current approved indications for use
- Subjects who give consent for their participation
- Subjects participating in another clinical study that may impact the follow-up or results of this study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Participants With Mitral Valve Regurgitation Severity ≤2+ at 30 Days At 30 days Mitral Valve Regurgitation (MR) Severity of 2+ or less at 30 days
Occurrence of Major Adverse Events (MAE) at 30 Days At 30 days MAE is defined as a composite of all-cause Death, Myocardial Infarction, Stroke, or non-elective Cardiovascular (CV) surgery for device related complications.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (63)
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Cardiology Associates of Mobile, Inc.
🇺🇸Mobile, Alabama, United States
Arkansas Heart Hospital
🇺🇸Little Rock, Arkansas, United States
Scripps Health
🇺🇸La Jolla, California, United States
University of California - Davis Medical Center
🇺🇸Sacramento, California, United States
Los Robles Regional Medical Center
🇺🇸Thousand Oaks, California, United States
Cardiology Associates of Fairfield County, PC
🇺🇸Norwalk, Connecticut, United States
NCH Healthcare System
🇺🇸Naples, Florida, United States
Northshore University Health System
🇺🇸Evanston, Illinois, United States
Prairie Education & Research
🇺🇸Springfield, Illinois, United States
Scroll for more (53 remaining)University of Alabama at Birmingham🇺🇸Birmingham, Alabama, United States